secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001193125-24-075211
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX appoints Zhen Su to Board; adopts amended bylaws for stockholder proposals
--------------------------------------------------------------------------------

- Zhen Su, M.D., M.B.A., appointed to Board as Class I director effective March 20, 2024, filling a vacancy.
- Dr. Su receives standard non-employee director compensation and an option to purchase 76,000 shares vesting over three years.
- Board adopted Amended and Restated Bylaws to modernize stockholder nomination and proposal procedures, including removal of 'acting in concert' provisions.
- Bylaw amendments effective immediately with clarifying and technical changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312524075211/0001193125-24-075211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312524075211/d803852d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-075211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer